ANXA1 and cancer: A suppression of CD8+ cytotoxic T cells and an expansion of the Tregs population may also be induced by ANXA1 overexpression in TME by FPR2/STAT3 signaling activation, contributing to therapy resistance in several cancer types, including CRC [38,141] (Figure 2).